Clinical trial
Alemtuzumab Induction in Islet Transplantation
NCT00175253 · University of Alberta, Other · Completed
Key facts
| NCT number | NCT00175253 |
|---|---|
| Title | Alemtuzumab Induction in Islet Transplantation |
| Official title | Alemtuzumab Induction With Tacrolimus and MMF Maintenance Immunosuppression in Islet Transplantation |
| Lead sponsor | University of Alberta, Other |
| Collaborators | Juvenile Diabetes Research Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes |
| Intervention type | Drug, Procedure |
| Interventions | alemtuzumab, islet transplant |
| Enrollment | 12 |
| Start date | Nov 1, 2005 |
| Completion | Apr 1, 2012 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 12, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: